With the recent FDA approval of TrikaftaTM, a triple combination therapy consisting of two distinct CFTR correctors, tezacaftor and elexacaftor (VX-445), and potentiator ivacaftor, 82 to 90% of CF patients will soon qualify for a CFTR-targeting therapy. This evidence concerns the gene CFTR and cystic fibrosis.